Cargando…

The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells

Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor involved in homeostatic regulation of normal cells and carcinogenesis of epithelial malignancies. With rapid development of the precision medicine era, a series of new therapies targeting EGFR are underway. Four EGFR monoclonal an...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Wen-Qi, Zeng, Li-Si, Wang, Li-Feng, Wang, Ying-Ying, Cheng, Jun-Ting, Zhang, Ying, Han, Zi-Wen, Zhou, Yang, Huang, Shao-Li, Wang, Xian-Wang, Peng, Xiao-Chun, Xiang, Ying, Ma, Zhaowu, Cui, Shu-Zhong, Xin, Hong-Wu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393266/
https://www.ncbi.nlm.nih.gov/pubmed/32793499
http://dx.doi.org/10.3389/fonc.2020.01249
_version_ 1783565010145902592
author Cai, Wen-Qi
Zeng, Li-Si
Wang, Li-Feng
Wang, Ying-Ying
Cheng, Jun-Ting
Zhang, Ying
Han, Zi-Wen
Zhou, Yang
Huang, Shao-Li
Wang, Xian-Wang
Peng, Xiao-Chun
Xiang, Ying
Ma, Zhaowu
Cui, Shu-Zhong
Xin, Hong-Wu
author_facet Cai, Wen-Qi
Zeng, Li-Si
Wang, Li-Feng
Wang, Ying-Ying
Cheng, Jun-Ting
Zhang, Ying
Han, Zi-Wen
Zhou, Yang
Huang, Shao-Li
Wang, Xian-Wang
Peng, Xiao-Chun
Xiang, Ying
Ma, Zhaowu
Cui, Shu-Zhong
Xin, Hong-Wu
author_sort Cai, Wen-Qi
collection PubMed
description Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor involved in homeostatic regulation of normal cells and carcinogenesis of epithelial malignancies. With rapid development of the precision medicine era, a series of new therapies targeting EGFR are underway. Four EGFR monoclonal antibody drugs (cetuximab, panitumumab, nimotuzumab, and necitumumab) are already on the market, and a dozen other EGFR monoclonal antibodies are in clinical trials. Here, we comprehensively review the newly identified biological properties and anti-tumor mechanisms of EGFR monoclonal antibodies. We summarize recently completed and ongoing clinical trials of the classic and new EGFR monoclonal antibodies. More importantly, according to our new standard, we re-classify the complex evolving tumor cell resistance mechanisms, including those involving exosomes, non-coding RNA and the tumor microenvironment, against EGFR monoclonal antibodies. Finally, we analyzed the limitations of EGFR monoclonal antibody therapy, and discussed the current strategies overcoming EGFR related drug resistance. This review will help us better understand the latest battles between EGFR monoclonal antibodies and resistant tumor cells, and the future directions to develop anti-tumor EGFR monoclonal antibodies with durable effects.
format Online
Article
Text
id pubmed-7393266
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-73932662020-08-12 The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells Cai, Wen-Qi Zeng, Li-Si Wang, Li-Feng Wang, Ying-Ying Cheng, Jun-Ting Zhang, Ying Han, Zi-Wen Zhou, Yang Huang, Shao-Li Wang, Xian-Wang Peng, Xiao-Chun Xiang, Ying Ma, Zhaowu Cui, Shu-Zhong Xin, Hong-Wu Front Oncol Oncology Epidermal growth factor receptor (EGFR) is a tyrosine kinase receptor involved in homeostatic regulation of normal cells and carcinogenesis of epithelial malignancies. With rapid development of the precision medicine era, a series of new therapies targeting EGFR are underway. Four EGFR monoclonal antibody drugs (cetuximab, panitumumab, nimotuzumab, and necitumumab) are already on the market, and a dozen other EGFR monoclonal antibodies are in clinical trials. Here, we comprehensively review the newly identified biological properties and anti-tumor mechanisms of EGFR monoclonal antibodies. We summarize recently completed and ongoing clinical trials of the classic and new EGFR monoclonal antibodies. More importantly, according to our new standard, we re-classify the complex evolving tumor cell resistance mechanisms, including those involving exosomes, non-coding RNA and the tumor microenvironment, against EGFR monoclonal antibodies. Finally, we analyzed the limitations of EGFR monoclonal antibody therapy, and discussed the current strategies overcoming EGFR related drug resistance. This review will help us better understand the latest battles between EGFR monoclonal antibodies and resistant tumor cells, and the future directions to develop anti-tumor EGFR monoclonal antibodies with durable effects. Frontiers Media S.A. 2020-07-24 /pmc/articles/PMC7393266/ /pubmed/32793499 http://dx.doi.org/10.3389/fonc.2020.01249 Text en Copyright © 2020 Cai, Zeng, Wang, Wang, Cheng, Zhang, Han, Zhou, Huang, Wang, Peng, Xiang, Ma, Cui and Xin. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cai, Wen-Qi
Zeng, Li-Si
Wang, Li-Feng
Wang, Ying-Ying
Cheng, Jun-Ting
Zhang, Ying
Han, Zi-Wen
Zhou, Yang
Huang, Shao-Li
Wang, Xian-Wang
Peng, Xiao-Chun
Xiang, Ying
Ma, Zhaowu
Cui, Shu-Zhong
Xin, Hong-Wu
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
title The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
title_full The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
title_fullStr The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
title_full_unstemmed The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
title_short The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
title_sort latest battles between egfr monoclonal antibodies and resistant tumor cells
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7393266/
https://www.ncbi.nlm.nih.gov/pubmed/32793499
http://dx.doi.org/10.3389/fonc.2020.01249
work_keys_str_mv AT caiwenqi thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT zenglisi thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT wanglifeng thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT wangyingying thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT chengjunting thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT zhangying thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT hanziwen thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT zhouyang thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT huangshaoli thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT wangxianwang thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT pengxiaochun thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT xiangying thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT mazhaowu thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT cuishuzhong thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT xinhongwu thelatestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT caiwenqi latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT zenglisi latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT wanglifeng latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT wangyingying latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT chengjunting latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT zhangying latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT hanziwen latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT zhouyang latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT huangshaoli latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT wangxianwang latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT pengxiaochun latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT xiangying latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT mazhaowu latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT cuishuzhong latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells
AT xinhongwu latestbattlesbetweenegfrmonoclonalantibodiesandresistanttumorcells